Proteomic Analysis of Human Serum from Patients with Chronic Kidney Disease

Romanova, Yulia; Laikov, Alexander; Markelova, Maria; Khadiullina, Rania; Максеев, А. Р.; Hasanova, Milausha; Rizvanov, Albert A.; Khaiboullina, Svetlana; Салафутдинов, И. И.

doi:10.3390/biom10020257

Cited by 45 publications

(34 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MRM assays are usually used for the detection of special biomarkers, diagnosis [ 24 , 25 , 26 , 27 ] and disease status confirmation. They are likewise used for the detection of different chemical compounds in nature [ 28 , 29 , 30 , 31 , 32 , 33 ].…”

Section: Discussionmentioning

confidence: 99%

Label-Free Multiple Reaction Monitoring, a Promising Method for Quantification Analyses of Specific Proteins in Bacteria

Toymentseva¹,

Koryagina²,

Laikov³

et al. 2020

IJMS

View full text Add to dashboard Cite

Bacillus subtilis produces eight industrially important exo-proteases. For the detection of proteases, the activity- and antibody-based assays are normally used. Current activity-based assays require expensive multiplex chemical substrates which allow specificity determination of each enzyme. In this study, we provide evidences pertaining to the usefulness of the label-free multiple reaction monitoring (MRM) assay for a rapid identification and quantitation of specific proteins in bacteria. We used wild-type B. pumilus cells producing at least two serine proteases, subtilisin-like protease (AprBp) and glutamyl endopeptidase (GseBp), as well as optimized recombinant B. subtilis cells containing the same protease genes under control of the LIKE expression system. The Skyline software was used for the selection of three specific proteotypic peptides and their fragment ions for quantification and confirmation of AprBp and GseBp in complex mixtures. MRM indicated that the production of AprBp and GseBp exo-enzymes were respectively 0.9- and 26.6-fold higher in the culture medium of B. pumilus strain in comparison to the recombinant B. subtilis strains carrying optimized LIKE expression systems under identical conditions. The developed procedure in this study is fast, easy to perform and dependable. Additionally, it achieves accurate proteins identification and quantification in complex mixture.

show abstract

Section: Discussionmentioning

confidence: 99%

Label-Free Multiple Reaction Monitoring, a Promising Method for Quantification Analyses of Specific Proteins in Bacteria

Toymentseva¹,

Koryagina²,

Laikov³

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Increased levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) involved in the inflammatory response predict poor outcome in patients with renal disease [112]. A proteomic approach identified an increased expression of serum IL-6 and TNF-α in the early stages of CKD, which highlights the importance of these inflammatory biomarkers for CKD patients' diagnoses and management [113]. An observational study conducted by Kamińska et al (2019), associated IL-6, but not TNF-α, to coronary artery calcification, a risk factor for cardiovascular mortality, in CKD and ESRD patients [114].…”

Section: Biomarkers Of Inflammationmentioning

confidence: 99%

“…The overexpression of other pro-inflammatory cytokines, such as interleukin-8 (IL-8) and interleukin-18 (IL-18), has also been linked to renal function decline [113,115,116]. Likewise, soluble TNF receptors 1 and 2 (sTNFR1 and sTNFR2) showed an important role in the progression of atherosclerosis and kidney diseases [117,118].…”

Section: Biomarkers Of Inflammationmentioning

confidence: 99%

New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature

Lousa

Reis

Beirão

et al. 2020

IJMS

View full text Add to dashboard Cite

The prevalence of chronic kidney disease (CKD) is increasing worldwide, and the mortality rate continues to be unacceptably high. The biomarkers currently used in clinical practice are considered relevant when there is already significant renal impairment compromising the early use of potentially successful therapeutic interventions. More sensitive and specific biomarkers to detect CKD earlier on and improve patients’ prognoses are an important unmet medical need. The aim of this review is to summarize the recent literature on new promising early CKD biomarkers of renal function, tubular lesions, endothelial dysfunction and inflammation, and on the auspicious findings from metabolomic studies in this field. Most of the studied biomarkers require further validation in large studies and in a broad range of populations in order to be implemented into routine CKD management. A panel of biomarkers, including earlier biomarkers of renal damage, seems to be a reasonable approach to be applied in clinical practice to allow earlier diagnosis and better disease characterization based on the underlying etiologic process.

show abstract

“…An elevated number of circulating Th17 cells were found in ESRD and kidney-transplanted patients [ 103 ]. More recently, proteomic analyses showed that serum IL-17A levels are significantly higher in CKD patients than in healthy controls [ 104 ]. Consistent with these findings, CKD stage positively correlated with the Th17/Treg ratio and serum IL-17A levels whereas it negatively correlated with serum IL-10 levels.…”

Section: Il-17a: a Key Proinflammatory Cytokine And Therapeutic Tamentioning

confidence: 99%

IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis

et al. 2020

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a health problem reaching epidemic proportions. There is no cure for CKD, and patients may progress to end-stage renal disease (ESRD). Peritoneal dialysis (PD) is a current replacement therapy option for ESRD patients until renal transplantation can be achieved. One important problem in long-term PD patients is peritoneal membrane failure. The mechanisms involved in peritoneal damage include activation of the inflammatory and immune responses, associated with submesothelial immune infiltrates, angiogenesis, loss of the mesothelial layer due to cell death and mesothelial to mesenchymal transition, and collagen accumulation in the submesothelial compact zone. These processes lead to fibrosis and loss of peritoneal membrane function. Peritoneal inflammation and membrane failure are strongly associated with additional problems in PD patients, mainly with a very high risk of cardiovascular disease. Among the inflammatory mediators involved in peritoneal damage, cytokine IL-17A has recently been proposed as a potential therapeutic target for chronic inflammatory diseases, including CKD. Although IL-17A is the hallmark cytokine of Th17 immune cells, many other cells can also produce or secrete IL-17A. In the peritoneum of PD patients, IL-17A-secreting cells comprise Th17 cells, γδ T cells, mast cells, and neutrophils. Experimental studies demonstrated that IL-17A blockade ameliorated peritoneal damage caused by exposure to PD fluids. This article provides a comprehensive review of recent advances on the role of IL-17A in peritoneal membrane injury during PD and other PD-associated complications.

show abstract

Proteomic Analysis of Human Serum from Patients with Chronic Kidney Disease

Cited by 45 publications

References 71 publications

Label-Free Multiple Reaction Monitoring, a Promising Method for Quantification Analyses of Specific Proteins in Bacteria

Label-Free Multiple Reaction Monitoring, a Promising Method for Quantification Analyses of Specific Proteins in Bacteria

New Potential Biomarkers for Chronic Kidney Disease Management—A Review of the Literature

IL-17A as a Potential Therapeutic Target for Patients on Peritoneal Dialysis

Contact Info

Product

Resources

About